Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States

被引：8

作者：

Tenforde, Mark W. ^{[1
]}

Self, Wesley H. ^{[2
]}

Zhu, Yuwei ^{[2
]}

Naioti, Eric A. ^{[1
]}

Gaglani, Manjusha ^{[3
,4
]}

Ginde, Adit A. ^{[5
]}

Jensen, Kelly ^{[5
]}

Talbot, H. Keipp ^{[2
]}

Casey, Jonathan D. ^{[2
]}

Mohr, Nicholas M. ^{[6
]}

Zepeski, Anne ^{[6
]}

McNeal, Tresa ^{[3
,4
]}

Ghamande, Shekhar ^{[3
,4
]}

Gibbs, Kevin W. ^{[7
]}

Files, D. Clark ^{[7
]}

Hager, David N. ^{[8
]}

Shehu, Arber ^{[8
]}

Prekker, Matthew E. ^{[9
]}

Erickson, Heidi L. ^{[9
]}

Gong, Michelle N. ^{[10
]}

Mohamed, Amira ^{[10
]}

Johnson, Nicholas J. ^{[11
]}

Srinivasan, Vasisht ^{[11
]}

Steingrub, Jay S. ^{[12
]}

Peltan, Ithan D. ^{[13
,14
]}

Brown, Samuel M. ^{[13
,14
]}

Martin, Emily T. ^{[14
,15
]}

Monto, Arnold S. ^{[14
,15
]}

Khan, Akram ^{[16
]}

Hough, Catherine L. ^{[16
]}

Busse, Laurence W. ^{[17
]}

ten Lohuis, Caitlin ^{[17
]}

Duggal, Abhijit ^{[18
]}

Wilson, Jennifer G. ^{[19
]}

Qadir, Nida ^{[20
]}

Chang, Steven Y. ^{[20
]}

Mallow, Christopher ^{[21
]}

Rivas, Carolina ^{[21
]}

Babcock, Hilary M. ^{[22
]}

Kwon, Jennie H. ^{[22
]}

Exline, Matthew C. ^{[23
]}

Botros, Mena M. ^{[23
]}

Lauring, Adam S. ^{[24
]}

Shapiro, Nathan, I ^{[25
]}

Halasa, Natasha ^{[2
]}

Chappell, James D. ^{[2
]}

Grijalva, Carlos G. ^{[2
]}

Rice, Todd W. ^{[2
]}

Jones, Ian D. ^{[2
]}

Stubblefield, William B. ^{[2
]}

机构：

[1] CDC COVID 19 Response Team, Atlanta, GA USA

[2] Vanderbilt Univ Sch Med, Nashville, TN USA

[3] Baylor Scott & White Hlth, Temple, TX USA

[4] Texas A&M Univ, Coll Med, Temple, TX USA

[5] Univ Colorado, Sch Med, Aurora, CO USA

[6] Univ Iowa, Iowa City, IA USA

[7] Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC USA

[8] Johns Hopkins Univ Hosp, Baltimore, MD USA

[9] Hennepin Cty Med Ctr, Minneapolis, MN USA

[10] Albert Einstein Coll Med, Montefiore Healthcare Ctr, Bronx, NY USA

[11] Univ Washington, Sch Med, Seattle, WA USA

[12] Baystate Med Ctr, Springfield, MA USA

[13] Intermountain Med Ctr, Salt Lake City, UT USA

[14] Univ Utah, Salt Lake City, UT USA

[15] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI USA

[16] Oregon Hlth & Sci Univ Hosp, Portland, OR USA

[17] Emory Univ, Sch Med, Atlanta, GA USA

[18] Cleveland Clin, Cleveland, OH USA

[19] Stanford Univ, Sch Med, Palo Alto, CA USA

[20] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA

[21] Univ Miami, Miami, FL USA

[22] Washington Univ, St Louis, MO USA

[23] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA

[24] Univ Michigan, Sch Med, Ann Arbor, MI USA

[25] Beth Israel Deaconess Med Ctr, Boston, MA USA

来源：

CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 03期

关键词：

COVID-19; duration of protection; waning; vaccine effectiveness; mRNA; COVID-19; VACCINES; SARS-COV-2; INFECTION; VACCINATION; BNT162B2; 2-DOSE;

D O I：

10.1093/cid/ciac381

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Among 10 078 adults hospitalized at 21 centers March-December 2021, 2-dose coronavirus disease 2019 (COVID-19) messenger RNA vaccine effectiveness (VE) in immunocompetent patients decreased from 90% to 82% at 6 months postvaccination. Background Coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines were authorized in the United States in December 2020. Although vaccine effectiveness (VE) against mild infection declines markedly after several months, limited understanding exists on the long-term durability of protection against COVID-19-associated hospitalization. Methods Case-control analysis of adults (>= 18 years) hospitalized at 21 hospitals in 18 states 11 March-15 December 2021, including COVID-19 case patients and reverse transcriptase-polymerase chain reaction-negative controls. We included adults who were unvaccinated or vaccinated with 2 doses of a mRNA vaccine before the date of illness onset. VE over time was assessed using logistic regression comparing odds of vaccination in cases versus controls, adjusting for confounders. Models included dichotomous time (<180 vs >= 180 days since dose 2) and continuous time modeled using restricted cubic splines. Results A total of 10 078 patients were included, 4906 cases (23% vaccinated) and 5172 controls (62% vaccinated). Median age was 60 years (interquartile range, 46-70), 56% were non-Hispanic White, and 81% had >= 1 medical condition. Among immunocompetent adults, VE <180 days was 90% (95% confidence interval [CI], 88-91) versus 82% (95% CI, 79-85) at >= 180 days (P < .001). VE declined for Pfizer-BioNTech (88% to 79%, P < .001) and Moderna (93% to 87%, P < .001) products, for younger adults (18-64 years) (91% to 87%, P = .005), and for adults >= 65 years of age (87% to 78%, P < .001). In models using restricted cubic splines, similar changes were observed. Conclusions In a period largely predating Omicron variant circulation, effectiveness of 2 mRNA doses against COVID-19-associated hospitalization was largely sustained through 9 months.

引用

页码：E460 / E468

页数：9

共 50 条

[41] A Descriptive Cohort Study of Drug Utilization Patterns Among Patients Hospitalized With Coronavirus Disease 2019 in the United States, January 2021-February 2022
Vititoe, Sarah E.
Govil, Priya
Baglivo, Aidan
Beebe, Elisha
Garry, Elizabeth M.
Gatto, Nicolle M.
Lasky, Tamar
Chakravarty, Aloka
Bradley, Marie C.
Perez-Vilar, Silvia
Rivera, Donna R.
Quinto, Kenneth
Clerman, Andrew
Rajpal, Anil
Frajzyngier, Vera
[J]. OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (07):
[42] Impact of Coronavirus Disease 2019 on Infectious Diseases Fellows in the United States: Perspectives From the First National Infectious Diseases Fellows Call
Nematollahi, Saman
Konold, Victoria J. L.
Gaston, David C.
Howard-Anderson, Jessica
Kiley, John L.
Masters, Mary C.
Melia, Michael T.
Balba, Gayle P.
Chiang, Augusto Dulanto
Gupta, Nupur
[J]. OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (02):
[43] Neutralizing Antibody Responses to Messenger RNA Coronavirus Disease 2019 Vaccines Versus Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Pregnant Women and Vaccine-Induced Antibody Transfer to Infants
Dawood, Fatimah S.
Tita, Alan
Stockwell, Melissa S.
Newes-Adeyi, Gabriella
Wielgosz, Kristina
Gyamfi-Bannerman, Cynthia
Battarbee, Ashley
Reichle, Lawrence
Thornburg, Natalie
Ellington, Sascha
Galang, Romeo R.
Vorwaller, Kelly
Vargas, Celibell Y.
Morrill, Tyler
Parks, Mickey
Powers, Emily
Gibson, Marie
Varner, Michael
[J]. OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (05):
[44] Prevalence and Severity of Food Insecurity Before and During the Coronavirus Disease 2019 Pandemic Among Adults and Youth in Australia, Canada, Chile, Mexico, the United Kingdom, and the United States
Pepetone, Alexandra
Frongillo, Edward A.
Dodd, Kevin W.
Wallace, Michael P.
Hammond, David
Kirkpatrick, Sharon I.
[J]. JOURNAL OF NUTRITION, 2023, 153 (04): : 1231 - 1243
[45] Characteristics of Adults Aged 18-49 Years Without Underlying Conditions Hospitalized With Laboratory-Confirmed Coronavirus Disease 2019 in the United States: COVID-NET March-August 2020
Owusu, Daniel
Kim, Lindsay
O'Halloran, Alissa
Whitaker, Michael
Piasecki, Alexandra M.
Reingold, Arthur
Alden, Nisha B.
Maslar, Amber
Anderson, Evan J.
Ryan, Patricia A.
Kim, Sue
Como-Sabetti, Kathryn
Hancock, Emily B.
Muse, Alison
Bennett, Nancy M.
Billing, Laurie M.
Sutton, Melissa
Talbot, H. Keipp
Ortega, Jake
Brammer, Lynnette
Fry, Alicia M.
Hall, Aron J.
Garg, Shikha
[J]. CLINICAL INFECTIOUS DISEASES, 2021, 72 (05) : E162 - E166
[46] Induction of High Neutralizing Activity Against Both Omicron BA.2 and Omicron BA.1 by Coronavirus Disease 2019 Messenger RNA Booster Vaccination
Tjan, Lidya Handayani
Furukawa, Koichi
Kurahashi, Yukiya
Sutandhio, Silvia
Nishimura, Mitsuhiro
Arii, Jun
Mori, Yasuko
[J]. JOURNAL OF INFECTIOUS DISEASES, 2022, 226 (08): : 1481 - 1483
[47] Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States
Moghadas, Seyed M.
Shoukat, Affan
Bawden, Carolyn E.
Langley, Joanne M.
Singer, Burton H.
Fitzpatrick, Meagan C.
Galvani, Alison P.
[J]. CLINICAL INFECTIOUS DISEASES, 2024, 78 (05) : 1328 - 1335
[48] Is Coronavirus Disease 2019 (COVID-19) Less Deadly Now? Trends in In-Hospital Mortality Among Hospitalized COVID-19 Patients in the United States
Moon, Rena C.
Mackey, Rachel H.
Cao, Zhun
Emont, Seth
Schott, Laura L.
Gayle, Julie
Lipkin, Craig
Rosenthal, Ning
[J]. CLINICAL INFECTIOUS DISEASES, 2022, 74 (12) : 2238 - 2242
[49] Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021
Tenforde, Mark W.
Olson, Samantha M.
Self, Wesley H.
Talbot, H. Keipp
Lindsell, Christopher J.
Steingrub, Jay S.
Shapiro, Nathan, I
Ginde, Adit A.
Douin, David J.
Prekker, Matthew E.
Brown, Samuel M.
Peltan, Ithan D.
Gong, Michelle N.
Mohamed, Amira
Khan, Akram
Aline, Matthew C.
Files, D. Clark
Gibbs, Kevin W.
Stubblefield, William B.
Casey, Jonathan D.
Rice, Todd W.
Grijalva, Carlos G.
Hager, David N.
Shehu, Arber
Qadir, Nida
Chang, Steven Y.
Wilson, Jennifer G.
Gaglani, Manjusha
Murthy, Kempapura
Calhoun, Nicole
Monto, Arnold S.
Martin, Emily T.
Malani, Anurag
Zimmerman, Richard K.
Silveira, Fernanda P.
Middleton, Donald B.
Zhu, Yuwei
Wyatt, Dayna
Stephenson, Meagan
Baughman, Adrienne
Womack, Kelsey N.
Hart, Kimberly W.
Kobayashi, Miwako
Verani, Jennifer R.
Patel, Manish M.
[J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2021, 70 (18): : 674 - 679
[50] Perinatally Human Immunodeficiency Virus-Infected Adolescents and Young Adults Demonstrate Distinct BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Immunogenicity
Morrocchi, Elena
Pighi, Chiara
Pascucci, Giuseppe Rubens
Cotugno, Nicola
Medri, Chiara
Amodio, Donato
Colagrossi, Luna
Ruggiero, Alessandra
Manno, Emma Concetta
Casamento Tumeo, Chiara
Bernardi, Stefania
Smolen, Kinga K.
Perno, Carlo Federico
Ozonoff, Al
Rossi, Paolo
Levy, Ofer
Palma, Paolo
[J]. CLINICAL INFECTIOUS DISEASES, 2022, 75 (SUPPL 1) : S51 - S60

← 1 2 3 4 5 →